HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Oct 15, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-10-13

Reporting Person: Peraza Lisa (VP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-13	Common Stock	M	552	—	Acquired	14388	Direct
2021-10-13	Common Stock	F	191	$10.55	Disposed	14197	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-13	Restricted Stock Units	$	M	552	Disposed		Common Stock (552)	Direct
2021-10-13	Employee Stock Option (Right to Buy)	$10.55	A	13013	Acquired	2031-10-13	Common Stock (13013)	Direct
2021-10-13	Restricted Stock Units	$0.00	A	23424	Acquired		Common Stock (23424)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.

F3: The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).

F4: The stock option vests and becomes exercisable monthly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that the stock option will be fully vested on the four year anniversary of the date of grant.

F5: The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant.